{"log_id": 4023826961615919463, "direction": 0, "words_result_num": 45, "words_result": [{"probability": {"variance": 0.00119, "average": 0.984569, "min": 0.832705}, "location": {"width": 524, "top": 179, "height": 32, "left": 202}, "words": "在使用扎那米书的任何时间都可以使用三价灭活流感疫苗"}, {"probability": {"variance": 7e-06, "average": 0.997751, "min": 0.992707}, "location": {"width": 114, "top": 236, "height": 27, "left": 209}, "words": "【药物过量】"}, {"probability": {"variance": 0.00883, "average": 0.968344, "min": 0.64337}, "location": {"width": 276, "top": 264, "height": 28, "left": 202}, "words": "尚无扎那米韦过量用药的报道"}, {"probability": {"variance": 0.028867, "average": 0.91642, "min": 0.075736}, "location": {"width": 933, "top": 286, "height": 36, "left": 88}, "words": " ong鉴于扎那米韦吸入给药且生物利用度很低(口服给药2%,吸入粉末为1020%),因此本"}, {"probability": {"variance": 0.029404, "average": 0.928388, "min": 0.354006}, "location": {"width": 915, "top": 316, "height": 35, "left": 106}, "words": "品不太可能发生意外的药物过量。已经证实,经鼻给予扎那米韦剂量达到96mg(约相"}, {"probability": {"variance": 0.014447, "average": 0.958844, "min": 0.385994}, "location": {"width": 799, "top": 345, "height": 33, "left": 207}, "words": "当于每口最大推荐剂的5倍)时,无不良反应发生。此外,连续5天静脉给药1200m"}, {"probability": {"variance": 0.000581, "average": 0.993069, "min": 0.891211}, "location": {"width": 399, "top": 378, "height": 25, "left": 206}, "words": "天,所达到的系统暴露量亦无不良反应发生"}, {"probability": {"variance": 0.006365, "average": 0.970359, "min": 0.66866}, "location": {"width": 340, "top": 406, "height": 26, "left": 203}, "words": "药物过敏事件发生后,无需特殊处理"}, {"probability": {"variance": 0, "average": 0.880304, "min": 0.880304}, "location": {"width": 26, "top": 473, "height": 25, "left": 101}, "words": "0"}, {"probability": {"variance": 3.4e-05, "average": 0.995533, "min": 0.985054}, "location": {"width": 113, "top": 458, "height": 25, "left": 210}, "words": "【临床试验】"}, {"probability": {"variance": 0.036166, "average": 0.881574, "min": 0.552361}, "location": {"width": 84, "top": 488, "height": 24, "left": 203}, "words": "流感治疗"}, {"probability": {"variance": 0.004696, "average": 0.978307, "min": 0.638805}, "location": {"width": 810, "top": 519, "height": 34, "left": 203}, "words": "成年人和青少年:已经在北美、南半球和欧洲各口的流感季节内进行安慰剂对照研究评价"}, {"probability": {"variance": 0.003253, "average": 0.982661, "min": 0.727538}, "location": {"width": 809, "top": 548, "height": 32, "left": 205}, "words": "扎那米韦10mg每天吸入两次治疗5天的有效性。治疗作用的程度在不同研究之间有差别"}, {"probability": {"variance": 0.006433, "average": 0.975355, "min": 0.593996}, "location": {"width": 520, "top": 578, "height": 30, "left": 207}, "words": "与人群的相关因素可能有关,包括用于缓解症状的药物量"}, {"probability": {"variance": 0.001038, "average": 0.986694, "min": 0.853624}, "location": {"width": 789, "top": 615, "height": 32, "left": 207}, "words": "研究人群:主要的Ⅲ期研究入选了1,588例12岁和12岁以上的患者(中位年龄34岁"}, {"probability": {"variance": 0.004826, "average": 0.977574, "min": 0.630426}, "location": {"width": 807, "top": 645, "height": 29, "left": 207}, "words": "49%为男性,91%为白种人),发生流感样疾病症状2天之内,没有合并症发生。通过培"}, {"probability": {"variance": 0.005461, "average": 0.982887, "min": 0.520629}, "location": {"width": 808, "top": 672, "height": 32, "left": 206}, "words": "养、血凝抑制抗体或试验性直接检测证实为流感。在证实为流感的1164例患者中,89%"}, {"probability": {"variance": 0.0092, "average": 0.971077, "min": 0.464848}, "location": {"width": 816, "top": 699, "height": 31, "left": 206}, "words": "为甲型流感,11%为乙型流感。这些研究作为有效性评价的主要依据,日期研究由于需要支"}, {"probability": {"variance": 0.001092, "average": 0.98588, "min": 0.84832}, "location": {"width": 812, "top": 726, "height": 33, "left": 203}, "words": "持信息,更为有限。随机至扎那米韦或安慰剂(吸入型乳糖赋形剂)组之后,所有患者都"}, {"probability": {"variance": 0.00139, "average": 0.989051, "min": 0.84474}, "location": {"width": 341, "top": 758, "height": 27, "left": 203}, "words": "接受指导,首次用药由一名医师监督"}, {"probability": {"variance": 0.01307, "average": 0.93419, "min": 0.618286}, "location": {"width": 792, "top": 793, "height": 33, "left": 209}, "words": "主要结果:至流感主要症状改善时间的定义包括没有发热和自我评价为“无”或“轻微“头痛"}, {"probability": {"variance": 0.021947, "average": 0.923916, "min": 0.360266}, "location": {"width": 813, "top": 822, "height": 31, "left": 203}, "words": "肌痛、咳嗽和喉痛。在北美共计600例以上流感阳性的患者)进行了一项Ⅱ期和Ⅲ期"}, {"probability": {"variance": 0.013923, "average": 0.9583, "min": 0.515078}, "location": {"width": 790, "top": 849, "height": 33, "left": 205}, "words": "究提示接受扎那米韦的患者与接受安慰剂的患者相比这一定义的症状改善时间要短1天"}, {"probability": {"variance": 0.004729, "average": 0.980672, "min": 0.583}, "location": {"width": 796, "top": 878, "height": 31, "left": 226}, "words": "项在南半球(321例流感阳性患者)进行的研究中,观察到症状改善时间的差异中位数为"}, {"probability": {"variance": 0.015881, "average": 0.955385, "min": 0.467219}, "location": {"width": 352, "top": 910, "height": 25, "left": 221}, "words": "5大。欧洲研究提供了其他有效性证据"}, {"probability": {"variance": 0.012041, "average": 0.971004, "min": 0.497548}, "location": {"width": 815, "top": 973, "height": 32, "left": 207}, "words": "其他发现:甲型流感和乙型流感患者相比没有发现一致的治疗作用差异:但是,这些试验"}, {"probability": {"variance": 0.000635, "average": 0.990064, "min": 0.854385}, "location": {"width": 817, "top": 1002, "height": 35, "left": 206}, "words": "入选的乙型流感病例数较少,因此提供的支持乙型流感的证据较少。一般来说,入组时体"}, {"probability": {"variance": 0.0029, "average": 0.981818, "min": 0.68609}, "location": {"width": 820, "top": 1031, "height": 33, "left": 203}, "words": "温较低(例如38.2℃或更低)的患者或者研究者评价为症状严重程度较低的患者从治疗中受"}, {"probability": {"variance": 0.003082, "average": 0.977615, "min": 0.761823}, "location": {"width": 817, "top": 1059, "height": 34, "left": 205}, "words": "益较少。在患有基础慢性医学疾病(包括呼吸或心血管)的患者中没有证实治疗作用《见"}, {"probability": {"variance": 0.011359, "average": 0.966344, "min": 0.363641}, "location": {"width": 818, "top": 1087, "height": 33, "left": 203}, "words": "注意事项治疗组间没有发现并发症发生率的一致差异。在两个治疗组中主要研究重点"}, {"probability": {"variance": 0.000157, "average": 0.993844, "min": 0.962314}, "location": {"width": 273, "top": 1121, "height": 25, "left": 206}, "words": "之后观察到一些症状起伏现象"}, {"probability": {"variance": 0.000505, "average": 0.991455, "min": 0.894971}, "location": {"width": 820, "top": 1169, "height": 36, "left": 204}, "words": "儿童患者:在北美和欧洲进行的一项安慰剂对照研究中评价了扎那米韦10mg每天吸入两次"}, {"probability": {"variance": 0.000253, "average": 0.992535, "min": 0.932917}, "location": {"width": 818, "top": 1199, "height": 32, "left": 205}, "words": "治疗5天对儿童患者治疗流感的有效性,研究入选471例患者,年龄从5至12岁(55%为男"}, {"probability": {"variance": 0.001372, "average": 0.984764, "min": 0.783789}, "location": {"width": 816, "top": 1226, "height": 32, "left": 205}, "words": "性,90%为白种人),均在症状发生36小时内。在证实流感的患者中,65%为甲型流感,35%"}, {"probability": {"variance": 0.000437, "average": 0.992218, "min": 0.896136}, "location": {"width": 815, "top": 1255, "height": 27, "left": 206}, "words": "为乙型流感。至改善时间的定义包括没有发热和父母评价没有或轻度咳嗽,没有轻微的肌"}, {"probability": {"variance": 0.013473, "average": 0.941366, "min": 0.573703}, "location": {"width": 814, "top": 1281, "height": 31, "left": 206}, "words": "痛和关节痛、咽痛、寒战/发热和头痛。接受扎那米韦的患者与安慰剂患者相比症状改善的"}, {"probability": {"variance": 0.008737, "average": 0.97003, "min": 0.445721}, "location": {"width": 803, "top": 1310, "height": 26, "left": 211}, "words": "位时间短1天。治疗组间没有观察到并发症发生率的一致差异。在两个治疗组中主要研"}, {"probability": {"variance": 0.000499, "average": 0.98682, "min": 0.912255}, "location": {"width": 337, "top": 1339, "height": 24, "left": 206}, "words": "究终点之后都发现一些症状起伏现象"}, {"probability": {"variance": 0.013971, "average": 0.974313, "min": 0.419915}, "location": {"width": 473, "top": 1389, "height": 27, "left": 204}, "words": "前还没有症状发作48小时后开始流感治疗的研究"}, {"probability": {"variance": 8e-06, "average": 0.997743, "min": 0.99346}, "location": {"width": 114, "top": 1441, "height": 26, "left": 211}, "words": "【药理毒理】"}, {"probability": {"variance": 0, "average": 0.999896, "min": 0.999798}, "location": {"width": 46, "top": 1471, "height": 23, "left": 204}, "words": "药理"}, {"probability": {"variance": 0.006724, "average": 0.965376, "min": 0.614992}, "location": {"width": 811, "top": 1493, "height": 27, "left": 203}, "words": "扎那米韦为一种神经氨酸酶(流行性感冒病毒表面酶)抑制剂,干扰病毒微粒的释放。扎"}, {"probability": {"variance": 0.004548, "average": 0.97759, "min": 0.653706}, "location": {"width": 809, "top": 1520, "height": 28, "left": 205}, "words": "那米韦在实验室和临床流感隔离群中的抗病毒活性已被培养细胞系证明。扎那米节抑制流"}, {"probability": {"variance": 0.005818, "average": 0.971707, "min": 0.607439}, "location": {"width": 816, "top": 1549, "height": 28, "left": 205}, "words": "感病毒所需的浓度在不同分析方法和测试病毒株中有很大的变化。扎那米韦50%利90%的有"}, {"probability": {"variance": 0, "average": 0.809256, "min": 0.809256}, "location": {"width": 29, "top": 1623, "height": 19, "left": 574}, "words": " age"}], "language": 3}